Copy Modified) PTO/SB/08A-B (10-96)
Approved for use through 103/199 OMB 0651-0031

Complete if Known

10/084/706 10/609,206 Substitute for form 1449A-B/PTO Complete if Known Application Number February 26, 2002 June 27, 2003 INFORMATION DISCLOSURE Filing Date STATEMENT BY APPLICANT First Named Inventor Rasmussen, et al. Group Art Unit 1647 Examiner Name J. Seharaseyon (use as many sheets as necessary) Attorney Docket Number 0228us410 0228us420

		U.S. Patent Do		S. PATENT DOCUMENTS  Name of Patentee or Applicant of	Date of Publication of	Pages, Columns, lines,
Examiner Initials	Cite No.	Number	Kind Code (if known)	Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appea
						ļ
	-					

					N PATENT DOCUMEN			
Examiner Initials	Cite No.	Office	Foreign Patent Docum Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	т
/JS/	1	EP	0 287 075	B2	Dr. Rentschler Biotechnologie GmbH	10/19/1988		X
/JS/	2	EP	0 287 075 (English language translation of document AY)	B2	Dr. Rentschler Biotechnologie GmbH	10/19/1988		
/JS/	3	wo	01/15736	A2	Maxygen ApS	03/08/2001		
								H
								1

Examiner	Cite	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS  Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal,	T
Initials	No.	serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	11
/JS/	4	O'CONNELL, et al., "The Influence of Flanking Sequences on O-Glycosylation", Biochemical and Biophysical Research Communications, 1991, pp. 1024-1030, 180:2.	
			Π

Examiner	/ I + b O - b /	Date	
Signature	/Jegatheesan Seharaseyon/	Considered	08/15/2007

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

		4/6	M .
Substitute for form 1449A-B/PTO	C	omplete if Known	Pt Applican
	Application Number	09/648,569 10/609,296	Cation
INFORMATION DISCLOSURE.	Filing Date	August 25, 2000 June 2	27, 2003
STATEMENT BY APPLICANT	First Named Inventor	A. H. Pedersen Poul B.	Rasmussen
	Group Art Unit	1647	
	Examiner Name	J. Seharaseyon	
(use as many sheets as necessary)	Attorney Docket Number	0202us810 0228us420	

			U.	S. PATENT DOCUMENTS		
		U.S. Patent Docu	ment	Name of Patentee or Applicant of	Date of Publication of	Pages, Columns, lines,
Examiner	Cite	Number	Kind Code	Cited Document	Cited Document	Where Relevant Passages
Initials	No.		(if known)		MM-DD-YYYY	or Relevant Figures Appea
/JS	1	5,206,344		Katre et al.	04/27/1993	
/JS/	2	5,738,846		Greenwald et al.	04/14/1998	

					N PATENT DOCUMEN			
Examiner Initials	Cite No.	Office	Foreign Patent Docu Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	т
/JS/	3	EP	0 370 205	A2	Kyowa Hakko Kogyo Co., Ltd.	05/30/1990		
	4	EP	0 529 300	B1	Rentschler Biotechnologie GmbH & Co.	03/03/93		×
	5	EP	0 529 300 (English language translation of document #4)	B1	Rentschler Biotechnologie GmbH & Co.	03/03/93		
	6	wo	95/27502	A1	Research Develop- ment Foundation	10/19/1995		
	7	wo	98/35026	A1	Novo Nordisk A/S	08/13/1998		
V	8	wo	99/55377	A2	Applied Research Systems	11/04/1999		
					-,			t

		OTHER ART - NON PATENT LITERATURE DOCUMENTS	_
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	_
/JS/	9	Derwent Abstract 012152872 for WO 98/48018, a German publication cited in previous IDS Form-1449.	Γ
/JS/	10	Derwent Abstract 009442954 for EP 539 300, a French publication cited in previous IDS Form-1449.	
			Γ

Examiner	/ Innethannan Cabaranayar/	Date	
Signature	/Jegatheesan Seharaseyon/	Considered	08/15/2007

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

COPY FROM PARENT

Examiner

Signature

Complete if Known Application Number BY APPLICANT STATEMENT BY APPLICANT Filing Date STATEMENT BY APPLICANT Group Art Unit Group Art Unit Complete if Known Application Number Belloade if Known Application Number Filing Date Andaren, Highlight Pedersen Poul Resynussien Group Art Unit He93- (5-47)	PY FROM PARENT	FARENT	(Modified) PTO/SB/08A-8 (10-96) approved for use through 10/31/99, OMB 0651-0031
INFORMATION DISCLOSURE Filing Date August 25, 2000 Tune 27, 2003  STATEMENT BY APPLICANT First Named Inventor Anders, Highboit Pedersen Poul Rasynuss en Group Art Unit 1693 - 16 47	Substitute for form 1449A-B/PTO	C	omplete if Known
Filing Date STATEMENT BY APPLICANT First Named Inventor Group Art Unit Figs. Andere, Highbot Pedersen Port Rasynussen Group Art Unit Figs. 7 (27) 2003 First Named Inventor Group Art Unit Figs. 7 (67)		Application Number	-09/648.569 10/609 29/
STATEMENT BY APPLICANT First Named Inventor Andaro, Hielhoft Pedersen Poul Rasyn of Sen		Filing Date	
Group Art Unit 1633 / 647	STATEMENT BY APPLICANT	First Named Inventor	
	.4	Group Art Unit	
Examiner Name Unassigned J Dehava to Vola	6	Examiner Name	Unassigned J. Scharaseyon
(use as many sheets as necessary)  Attorney Docket Number  31-107600US 0 228 US 42-0	(use as many sneets as necessary)	Attorney Docket Number	

			U.	S. PATENT DOCUMENTS	3	
Examiner Cite Initials No.		U.S. Patent Document Number Kind Code (if known)		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document Where Relevant Part MM-DD-YYYY or Relevant Figures	
/JS/	AA	4,588,585		Mark et al.	05-13-1986	
	AB	4,686,191		Itoh et al.	08-11-1987	
	AC	4,769,233		Bell et al.	09-06-1988	
	AD	4,904,584		Shaw	02-27-1990	
	AE	4,914,033		Bell et al.	04-03-1990	
Т	AF	4,917,888		Katre et al.	04-17-1990	
Т	AG	4,966,843		McCormick et al.	10-30-1990	
	АН	5,218,092		Sasaki et al.	08-06-1993	
	Al	5,376,567		McCormick et al.	12-27-1994	
	AJ	5,382,657		Hoffmann-La Roche Inc.	01-17-1995	
1/	AK	5,545,723		Goelz et al.	08-13-1996	
~	AL	5,795,779		McCormick et al.	08-18-1998	

	,			<u>FOREIGI</u>	N PATENT DOCUMEN	TS		_
Examin er Initials	Cite	<b>—</b> —	Foreign Patent Docu			Date of Publication	Pages, Columns, Lines,	_
	No.	Office	Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	of Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	Т
/JS/	ΑМ	wo	95/25170		Biogen, Inc.	09-21-1995		T
	AN	wo	98/48018		Fraun-Hofer- Gesellschaft Zur Forderung Der Angewandten	10-29-1998		
	AO	wo	99/03887		Bolder Biotechnology	01-28-1999		
	AP	wo	99/55377		Applied Research	11-04-1999		Г
	AQ	wo	99/67291		Immunex Corporation	12-29-1999		
V	AR	wo	00/23114		Biogen, Inc.	04-27-2000		T

	Considered	
*EXAMINER: Initial if reference considered, whether or not citation is in conforman conformance and not considered. Include copy of this form with next communication	ce with MPEP 609.	Draw line through citation if not in

/Jenatheesan Seharasevon/

Date

08/15/2007

COPY FROM PARENT

Substitute for form 1449A-B/PTO Complete if Known 09/648,569/0/609, 296 August 25, 2000 June 27, 2003 Application Number INFORMATION DISCLOSURE Filing Date STATEMENT BY APPLICANT First Named Inventor Anders, Hielholt Pedersen Poul Rasmussen Group Art Unit 1833 /647 **Examiner Name** Unassigned J. Scharaseyon (use as many sheets as necessary) Attorney Docket Number 31-107600US 0228US 420

/,	JS/	AS	wo	00/23472	Biogen, Inc.	04-27-2000	T
		AT	wo	00/26354	Novo Nordisk	05-11-2000	+
141		AU	EP	083 069	Kyowa Hakko Kogyo Co., Ltd.	09-16-1987	
		ΑV	EP	041 313	Biogen, Inc.	09-12-1990	+
		AW	EP	229 108	Cetus Corporation	12-27-1990	$\top$
		AX	EP	260 350	Cetus Corporation	02-12-1992	+
		AY	EP	287 075	Arzeneimittelforschung /Drug Research	01-18-1995	
***************************************		ΑZ	EP	539 300	Philippe Thiriet	02-07-1996	
V	/	ВА	EP	593 868	Hoffmann-La Roche	04-15-1998	

			OTHER PRIOR ART - NON PATECNT LITERATURE DOCUMENTS	_
	min er ials	Cile No.	include name of the author (in CAPITAL LETTERS), site of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	т
JS/   BB   Fierlbeck et al., "Neutralising interferon β antibodies in melanoma patients treated with recombinant and natural interferon β" Cancer Immunol Immunother (1994) 39:263-268				
		вс	Karpusas et al., "The Structure of Human Interferon- β: Implications for activity" CMLS 54 (1998) 1203-1216	
		BD	Carpusas et al. "The crystal structure of human interferon β at 2.2 A resolution" Proc. Nat. Acad. Sci. USA (1997) 94:11813-11818	
		BE	Nat. Acad. Sci. USA (1997) 94:11813-11818  Mayorga et al., "Antibodies to Commercially Available Interferon-Bet Molecules in Multipule Sclerosis Patients Treated with Natural Interferon-Beta" Int. Arch. Allery Immunol 1999; 118:368-371	
		BF	Munschauer et al., "Managing Side Effects of Interferon-Beta in Patients with Relapsing- Remitting Multipule Sclerosis" Clinical Therapeutics vol. 19, No. 5, 1997 883-893	
٧	/ .	BG	Redlich et al., "Antibodies that neutralize human ß interferon biologic activity recognizing a linear epitope: Analysis by synthetic peptide mapping" <a href="Proc. Natl. Acad. Sci. USA">Proc. Natl. Acad. Sci. USA</a> vol. 88, pp. 4040-4044 May 1991	

Examiner Signature	/Jegatheesan Seharaseyon/	Date Considered	08/15/2007	

## COPY FROM PARENT

	FROM PARENT	(Modified) PTO/SB/08A-B (10-96) pproved for use through 10/31/99, OMB 0651-0031	
Substitute for form 1449A-B/PTO	C	omplete if Known ,	
COK .	Application Number	09/648,569 10/609,296	
INFORMATION DISCLOSURE	Filing Date	August 25, 2000 June 27, 2003	
STATEMENT BY APPLICANT	First Named Inventor		use
	Group Art Unit	1633 /647 /	
	Examiner Name	Unassigned J. Scharaseyon	
(use as many sheets as necessary)	Attorney Docket Number	31-107600US 0228 US 420	

· /JS/	вн	Rudick et al., "Incidence and significance of neutralizing antibodies to interferon beta-1a in multipule sclerosis" Neurology May 1889, 50: 1266-1272
	ВІ	Runkel et al., "Structural and Functional Differences Between Glycosylated and Non-Glycosylated Forms of Human Interferon- β (IFN- β) Pharmaceutical Research vol. 15, No 4, 1998, 641-649
	BJ	Runkel et al, 1998, Jour. Biol. Chem. Difference in Activity between α and β Type 1 Interferons Explored by Mutational Analysis" 273, No. 14, pp. 8003-8008
	вк	Senda et al., "Refined Crystal Structure of Recombinant Murine Interferon- β at 2.15 A Resolution" J. Mil. Biol. (1995) 253, 187-207
	BL	Stewart et al, DNA "Chemical Mutagenesis of Human Interferon- β: Construction, Expression in E. coli, and Biological Activity of Sodium Bisulfite-Induced Mutations Vol 6 no 2 1987 p119-128
	вм	Tanigunchi, et al., "The nucleotide sequence of human fibroblast interferon cDNA"  Gene 10 (1980) 11-15
V	BN	Yong et al., "Interferon beta in the treatment of multiple sclerosis" Neurology 1998; 51: 682-689

Examiner	/Jegatheesan Seharasevon/	Date	08/15/2007
Signature	/Jegaineesan Senaraseyon/	Considered	00/13/2007

JUL 8 1 2005
Substitute for the 1449A-B/PTO
SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT BY
APPLICANT

C	omplete if Known	_
Application Number	10/609,296	_
Filing Date	June 27, 2003	_
First Named Inventor	Poul Baad Rasmussen	_
Group Art Unit	1647	_
Examiner Name	Jegatheesan Seharaseyon	_
Attomey Docket Number	0228us420	_

(use	as	many	sheets	as	necessary)	

		U.S. Patent Docume		. PATENT DOCUMENTS  Name of Patentee or Applicant of	Date of Publication of	Pages, Columns, lines,
Examiner Initials	Cite No.	Number Number	Kind Code (if known)	Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appeal
IJSi	1	6,531,122		Pedersen et al.	03-11-2003	
/J6/	2	2003/0175240A1 (USSN 10/325,720)		Pedersen et al.	09-18-2003	
ĴS/	3	2003/0170206A1 (USSN 10/084,706)	:	Rasmussen et al.	09-11-2003	

					N PATENT DOCUMEN			
		F	oreign Patent Docu			Date of Publication	Pages, Columns, Lines,	Г
Examiner Cite Initials No.	Office	Number	(if known)	Name of Patentee or Applicant of Cited Document	of Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	Ľ	
							-	Г
				1				Г

	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	_
Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	т
4	Apweiler et al., "On the frequency of protein glycosylation, as deducted from analysis of the SWISS-PROT database," Biochim. Biophys. Acta 1473:4-8 (1999).	
5	Wells et al., "Additivity of Mutational Effects in Proteins," Biochemistry 29(37):8509-8517 (1990).	
6	Ngo et al., "Computation Complexity, Protein Structure Prediction, and the Levinthal Paradox," in THE PROTEIN FOLDING PROBLEM AND TERTIARY STRUCTURE PREDICTION, pp. 492-495 (K. Merz Jr. and S. Le Grand, eds., 1994).	
	No. 4	Cite   Include name of the author (in CAPITAL LETTERS), the of the article (when appropriate), bite of the item (took, magazine, journal, serial, symposium, catalog, etc), date, page(g), volume-issue number(g), publisher, city and/or country where published.    Apweller et al., "On the frequency of protein glycosystation, as deducted from analysis of the SWISS-PROT database," Biochim. Biophys. Acta 1473:4-8 (1999).    Wells et al., "Additivity of Mutational Effects in Proteins," Biochemistry 29(37):8509-8517 (1990).    Wog et al., "Computation Complexity, Protein Structure Prediction, and the Levinthal Paradox," in The PROTEIN FOLDING PROBLEM AND TERTIARY STRUCTURE PREDICTION, pp. 492-495 (K. Merz

Examiner		Date	00// 5/00
Cionatura	/ Jenatheesan Seharasevon/	Considered	l 08/15/2007 I
Signature	roeganieesan oenaraseyon	Considered	00.10.2001

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.